The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

详细信息	查看全文 | 推荐本文 |

• 作者：Albert Jan van Hoek^a ; ^{albertjan.vanhoek@hpa.org.uk} ; Nick Andrews^b ; Pauline A. Waight^a ; Julia Stowe^a ; Peter Gates^c ; Robert George^d ; Elizabeth Miller^a
• 关键词：Invasive pneumococcal disease ; Hospitalisation ; Mortality ; Linkage ; Risk groups ; Vaccination ; Risk
• 刊名：Journal of Infection
• 出版年：2012
• 期刊代码：6_01634453
• 类别：imm
• 出版时间：July, 2012
• 卷：65
• 期：1
• 页码：17-24
• 文件大小：197 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Objective

To inform national policy making on the use of the 13-valent pneumococcal vaccine among risk groups we estimated the increased risk of invasive pneumococcal disease (IPD) outcomes among clinical risk groups. Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects.

Methods

Over 22,000 IPD patients in England (March 2002-March 2009 - aged 2 and over) were linked to their hospitalisation records. The prevalence of risk factors in these patients was compared to the prevalence of risk factors in the general population.

Results

There was an increased odds ratio (OR) for hospitalisation (OR 11.7 2-15 years; 7.6 16-64; 2.7 65+) and death (OR 2.4 2-15 years, 3.9 16-64, 1.2 65+) from IPD among risk group. The most important risk factors that predict IPD are chronic liver disease, immunosuppression, and chronic respiratory diseases. Herd protection effects due to introduction of the 7-valent vaccine were identical in both patient groups as shown by the similar decline in the proportion of IPD caused by PCV7 serotypes in risk and non-risk groups.

Conclusions

There is a marked increased risk of IPD among those with certain clinical conditions, suggesting potential benefit from a targeted vaccination approach. However, the indirect protection from conjugate vaccination of children suggests PCV vaccination of high-risk groups may not provide substantial additional benefit once herd immunity takes effect.